Human Rubella IgG ELISA kit

CAT#: EA100957

Human Rubella IgG ELISA kit

Specifications

Product Data

• Format: 8x12 divisible strips
• Assay Type: Solid Phase Sandwich ELISA
• Assay Length: 3 hours
• Signal: Colorimetric
• Sample Type: Serum
• Sample Volume: 10 µl/well
• Specificity: This kit is used for quantitative detection human Rubella IgG
• Reactivities: Human
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Interference: No significant interference observed with available related molecules.
• Components:
  • 1. Microwells coated with Rubella antigen: 12x8x1
  • 2. Sample Diluent: 1 bottle (ready to use): 22 ml
  • 3. Calibrator: 1 Vial (ready to use): 1ml
  • 4. Positive Control: 1 vial (ready to use): 1ml
  • 5. Negative Control:. 1 vial (ready to use): 1ml
  • 6. Enzyme conjugate: 1 bottle (ready to use): 12ml
  • 7. TMB Substrate: 1 bottle (ready to use): 12ml
  • 8. Stop Solution: 1 bottle (ready to use): 12ml
  • 9. Wash concentrate 20X: 1 bottle: 25ml
• Background: Rubella is usually a mild disease with infrequent complication. In unvaccinated populations, rubella is primarily a childhood disease. Where children are well-immunized, adolescent and adult infections become more evident. Rubella is spread by direct contact with nasal or throat secretions of infected individuals. Symptoms may include a rash, slight fever, joint aches, headache, discomfort, runny nose and reddened eyes. The incubation period for rubella is 12-23 days; in most cases, symptoms appear within 16-18 days. If contracted during the first trimester of pregnancy, Rubella infection can lead to congenital rubella syndrome (CRS). Infection of a pregnant woman may result in a miscarriage, stillbirth or the birth of an infant with abnormalities, which may include deafness, cataracts, heart defects, liver and spleen damage and mental retardation. CRS occurs among at least 25 percent of infants born to women who have had rubella during the first trimester of pregnancy. The presence of IgG antibody to rubella virus is indicative of vaccination or previous exposure. In individuals with acute rubella infection, four-fold or greater increase in IgG antibody level is indicative of recent infection. Rubella IgM antibodies are detected by ELISA in 100% of patients between days 11-25 after onset of the exanthema, in 60-80% of individuals at days 15-25 after vaccination and in 90-97% of infants with congenital rubella between 2 weeks and 3 months after birth. Rubella IgM antibody often persists for 20-30 days after acute infection or vaccination.